Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT00956059
Other study ID # CSX-090630-SAHXJTU
Secondary ID DBDZL-1DX-FSGS-1
Status Not yet recruiting
Phase N/A
First received August 10, 2009
Last updated August 10, 2009
Start date September 2009
Est. completion date December 2012

Study information

Verified date August 2009
Source Xi’an Jiaotong University College of Medicine
Contact Baosong Gui, MD
Phone 86-29-87679917
Email guibsdoctor@sina.com.cn
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

The aim of this clinical trial is to determine the effect and security of low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis.


Description:

Focal segmental glomerular sclerosis (FSGS) is characterized by heavy proteinuria and nephritic syndrome in clinic. The major pathological change is scarring of the glomerulus that is focal and segmental. The incidence of FSGS is increasing in recent years, but no unified protocol for FSGS treatment has been provided. Corticosteroid is the primary drug for FSGS treatment in clinic. However, corticosteroid treatment has a low response rate as 20% in clinic but some severe side-effects. The side-effects of long-term corticosteroid treatment urged researchers to find more reliable and secure methods for FSGS treatment. The new immunosuppressants shed light on FSGS treatment recently. The usage of immunosuppressants to FSGS treatment is in the preliminary stage and accounts for a few problems. The main problems include the uncertainty of curative effects, the lack of large-scale clinical trial, the side-effects of long-term application, and the high recurrence rate after withdraw. FSGS is immune-induced damage, which includes abnormality of many steps in humoral immunity and cellular immunity. According to it, we designed to inhibit the immune response at multi-targets with Prednisone Combined With MMF and FK506. Thus the dosage of these drugs can be decreased to a secure level for long-term treatment while the side-effects can be controlled well. Prednisone Combined With MMF and FK506 then can be used to FSGS treatment with effectiveness and security.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 70 Years
Eligibility Inclusion Criteria:

- Urinary protein=1.0g/24h

- Biopsy-proved FSGS

- Age=16years

- Understanding of the content of this study,signing informed consent form

- Adherence to drug taking and being able to be long-term followed up

Exclusion Criteria:

- Sharp deterioration of renal function

- Refractory hypertension

- Secondary FSGS

- Serious disease of liver,active stage of viral hepatitis,or AST?ALT=2.5 times of baseline

- Serious myelosuppression

- Being unable to be long-term followed up

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Focal Segmental Glomerulosclerosis
  • Glomerulosclerosis, Focal Segmental

Intervention

Drug:
prednisone, FK506, MMF
1.in the initial 3 months,prednisone dosage is 30mg per day;in the following 4~6 months,prednisone dose decreased to 20mg per day,then tapered gradually to 10mg per day;2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day,the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6~10µg/L);3. the initial dosage of MMF is 1.0g, twice per day,then reduce to 0.75 g, twice per day after 3 months
prednisone
In the initial 16~24 weeks,prednisone is given at full dose of 1mg/kg/d,then prednisone is tapered gradually,the whole course of treatment is 52 weeks

Locations

Country Name City State
China The second affiliated hospital of medical college, Xi'an Jiaotong University Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Xi’an Jiaotong University College of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary proteinuria,serum protein,Scr,blood routine examination,liver function test,blood glucose and lipid test 16~24 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT02585804 - Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects Phase 4
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Recruiting NCT05583942 - A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) N/A
Recruiting NCT05588063 - taVNS for FRNS in Children N/A
Completed NCT04369183 - Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
Recruiting NCT02896270 - Valproic Acid for Idiopathic Nephrotic Syndrome Phase 2/Phase 3
Completed NCT01113385 - Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome N/A
Terminated NCT00883636 - Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis N/A
Completed NCT04009668 - Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Phase 2
Terminated NCT03703908 - A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome Phase 2
Completed NCT03649152 - Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan Phase 2
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT00255398 - Kidney Disease Biomarkers
Terminated NCT05441826 - Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) Phase 2
Recruiting NCT02235857 - Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children N/A
Recruiting NCT05942625 - A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects Phase 1
Recruiting NCT02382874 - Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) Phase 1
Completed NCT00464321 - Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS Phase 1
Completed NCT03536754 - A Study of CCX140-B in Subjects With FSGS Phase 2
Recruiting NCT03929887 - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis